|
DexCom Stage: Venture Date of Investment: 2004 Web Site : http://www.dexcom.com Stock Symbol : NASDAQ: DXCM |
 |
DexCom, Inc., headquartered in San Diego, California, is focused on developing implantable sensors for the continuous monitoring of glucose in people with diabetes. Continuous glucose monitors represent the next stage in technological evolution from the currently available discrete testing devices, which can be both painful and cumbersome for diabetics, while providing limited information for treatment decisions. In 2004, Warburg Pincus invested $14.5 million in a $22.5 million Series D financing to continue development of DexCom’s sensor products and fund upcoming clinical trials. In 2005, DexCom completed its initial public offering, selling 4.7 million shares at $12.00 per share and generating net proceeds of $52.5 million.
